Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Celestica | Pfizer | |
|---|---|---|
| Moat rating | narrow The FY2025 10-K shows a real but bounded edge. On the durable side, Celestica is increasingly engaged as an ODM: its HPS business co-designs (JDM) or fully designs the platforms it builds, it states 'We have hardware and software patents that are integral to our HPS business' and that 'our increased R&D activities have resulted in the growth of our dependence on our patent portfolio', and HPS reached 41% of total revenue in 2025 (from 21% in 2023) at a margin profile the filing says is higher than traditional EMS work. On the limiting side, the same filing concedes 'Some of our competitors have greater scale and provide a broader range of services than we provide', the master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', work is won 'on a program-by-program basis', and the top 10 customers were 79% of 2025 revenue with three customers individually at 32%, 14% and 12%. An advantage that must be re-won each program against greater-scale rivals, for a handful of buyers who can in-source, is narrow rather than wide. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs Cost scale is explicitly not the source: the 10-K states competitors have greater scale and a broader service range. What does bind a customer is the design-in. Within HPS, Celestica 'design[s] and manufacture[s] products, either as customized solutions, white box solutions or under Joint Design and Manufacturing (JDM) engagements', holds 'hardware and software patents that are integral to our HPS business', and delivers 'complete platform solutions... integration and orchestration of various technologies into rack-scale designs'. The filing adds that 'a majority of these supply agreements also require the customer to purchase unused inventory that we have purchased to fulfill that customer's forecasted manufacturing demand', a contractual cost of walking away mid-program. Moving a qualified, jointly designed rack-scale platform to another ODM means requalifying a design Celestica partly owns, which is friction the commodity assembly work does not carry. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | at parity The 10-K claims no share leadership. It states plainly that 'Some of our competitors have greater scale and provide a broader range of services than we provide', and lists Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus in EMS plus Quanta, Wiwynn and Accton in ODM. Its stated competitive advantage is execution quality, not position: 'our track record in advanced manufacturing capabilities, design and engineering, quality, delivery, managing complexity and responsiveness'. It is also winning: CCS revenue grew 42% to $9.19 billion and total revenue reached $12.39 billion in FY2025. Competing on comparable terms with a field it neither leads nor trails is parity. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak The filing describes price as contested by contract, not set by Celestica: master supply agreements 'do not typically guarantee a particular level of business or fixed pricing', 'Some of these agreements require us to provide specific price reductions to our customers over the term of the contracts', and the Item 1A risk factor 'We operate in an industry comprised of numerous competitors and aggressive pricing dynamics' says competitors may be 'willing to, or able to make sales or provide services at lower margins than we do'. The site's fundamentals show gross margin at 12.06% in FY2025, up from 8.96% in FY2022, 9.47% in FY2023 and 10.72% in FY2024 — improving, but still low double digits, and the filing attributes the higher margin to mix (HPS is 'higher margin profile than our traditional EMS businesses' and went from 21% to 41% of revenue over the same span) rather than to raising prices. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Celestica is a contract design and manufacturing company that has been pulled up the value chain by the AI data-center build-out. Its CCS segment, which builds networking switches, optical systems, data center racks, servers and storage for hyperscalers and other cloud and AI service providers, grew 42% to $9.19 billion in 2025, and Communications alone went from 33% of revenue in 2023 to 57% in 2025. The part of that business with a defensible position is HPS, where Celestica is the designer rather than the assembler: HPS revenue rose 81% in 2025 to 41% of the total, carries a higher margin than traditional EMS work, and rests on a patent portfolio the filing calls integral to the business. That design-in position is what separates it from pure build-to-print capacity. What caps the moat is the customer side of the ledger. The 10-K describes an industry where 'aggressive pricing is a common business dynamic', where master supply agreements guarantee neither volume nor price and some of them 'require us to provide specific price reductions to our customers over the term of the contracts', and where the company bids program by program against Hon Hai, Flex, Jabil, Sanmina, Benchmark and Plexus on the EMS side and Quanta, Wiwynn and Accton on the ODM side, plus Arista and Cisco where a customer might buy an off-the-shelf switch instead. Revenue concentration has tightened as the AI mix grew, from 64% of revenue in the top 10 customers in 2023 to 79% in 2025, with a single customer at 32%. The company also notes its HPS offerings can compete with a customer's own hardware, which may 'negatively impact our relationship with, or result in a loss of business from, such customers'. So the profile is a genuine but program-scoped advantage, held by a company whose fortunes turn on a few buyers' capital plans. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Celestica sits between component suppliers and the hyperscale buyer, and owns the design only in part of that span. It 'procure[s] substantially all of our materials and components on behalf of our customers pursuant to individual purchase orders that are generally short-term in nature', then designs, assembles, integrates at rack scale and tests the switches, optical systems, servers, storage and data-center racks that cloud, AI and enterprise customers deploy. In ATS it is a pure EMS contractor that does 'not generally collaborate with ATS customers on the design of the solutions we manufacture'; in HPS it is the designer of record or a joint designer. The economics follow that split: the segment where it holds design IP is the one with the higher margin profile. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |